Ilex/Lilly Development Agreement Grows Out Of CRO Contract For Cancer Drug
Executive Summary
Ilex Oncology will initiate Phase II trials for Lilly's diarysulfonylurea anticancer compound LY295501 in mid-1999. The drug developer and contract research service provider is currently writing protocols for four Phase II studies in lung, ovarian and kidney cancer and melanoma.